ATE334985T1 - Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe - Google Patents

Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe

Info

Publication number
ATE334985T1
ATE334985T1 AT00959578T AT00959578T ATE334985T1 AT E334985 T1 ATE334985 T1 AT E334985T1 AT 00959578 T AT00959578 T AT 00959578T AT 00959578 T AT00959578 T AT 00959578T AT E334985 T1 ATE334985 T1 AT E334985T1
Authority
AT
Austria
Prior art keywords
damage
compounds
methods
nervous
treatment
Prior art date
Application number
AT00959578T
Other languages
English (en)
Inventor
Jia-He Li
Jie Zhang
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Application granted granted Critical
Publication of ATE334985T1 publication Critical patent/ATE334985T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
AT00959578T 1999-09-01 2000-08-30 Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe ATE334985T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/387,767 US6291425B1 (en) 1999-09-01 1999-09-01 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage

Publications (1)

Publication Number Publication Date
ATE334985T1 true ATE334985T1 (de) 2006-08-15

Family

ID=23531306

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959578T ATE334985T1 (de) 1999-09-01 2000-08-30 Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe

Country Status (9)

Country Link
US (3) US6291425B1 (de)
EP (1) EP1212328B1 (de)
JP (1) JP2003508400A (de)
AT (1) ATE334985T1 (de)
AU (1) AU7087100A (de)
CA (1) CA2382317C (de)
DE (1) DE60029799T2 (de)
MX (1) MXPA02002213A (de)
WO (1) WO2001016137A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
AU783393B2 (en) * 2000-03-20 2005-10-20 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
US6545011B2 (en) 2000-07-13 2003-04-08 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6497896B2 (en) * 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6534080B2 (en) * 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
EP1935885A3 (de) * 2001-05-22 2008-10-15 Neurogen Corporation Rezeptorliganden des melaninkonzentrierenden Hormons: substituierte 1-Benzyl-4-Aryl-Piperazinanaloga
CA2448080A1 (en) * 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2003014121A1 (en) * 2001-08-07 2003-02-20 Guilford Pharmaceuticals Inc. Compounds, derivatives, compositions, preparation and uses
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JPWO2006035673A1 (ja) * 2004-09-28 2008-05-15 独立行政法人科学技術振興機構 虚血性心臓傷害の新保護法
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CA2667890C (en) * 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
US20100137976A1 (en) * 2008-12-02 2010-06-03 Medtronic Vascular, Inc. Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
KR101827444B1 (ko) 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
CN104725389B (zh) * 2015-02-11 2017-03-01 中国科学院成都生物研究所 黑三棱内酯b衍生物及其制备方法和用途
CN104945406B (zh) * 2015-05-25 2017-10-10 苏州康润医药有限公司 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018258284A1 (en) 2017-04-24 2019-12-19 Mercaptor Discoveries, Inc. Use of thiol compounds to treat neurological disease
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1895105A (en) 1933-01-24 Cubt bath
US1880441A (en) 1932-10-04 Etjbole m
BE628255A (de)
US2467692A (en) 1949-04-19 Naphthyridones and processes fob
DE282711C (de)
US932290A (en) 1908-03-24 1909-08-24 Basf Ag Compound of the anthracene series and process of making same.
US1001325A (en) 1910-11-02 1911-08-22 Agfa Ag Product of the anthraquinone series and process of making same.
US1253252A (en) 1914-04-15 1918-01-15 Basf Ag Bluish-green vat dyes and process of making them.
US2593798A (en) 1947-05-22 1952-04-22 Searle & Co Aminoalkylamino isoquinoline compounds
US2612503A (en) 1949-04-19 1952-09-30 Smith Kline French Lab Basic ether-substituted isoquinolines
US2638472A (en) 1949-08-26 1953-05-12 Hoffmann La Roche 1-benzyl-5, 6, 7, 8-tetrahydroisoquinoline and derivatives thereof
US2666059A (en) 1950-08-11 1954-01-12 American Cyanamid Co Anilinoisoquinolines and processes of preparing the same
US2700040A (en) 1951-05-21 1955-01-18 Smith Kline French Lab Aminoalkylaminoisoquinolines
DE963184C (de) 1955-07-24 1957-05-02 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von haltbaren Loesungen von Salzen der 1-Dialkylaminoalkoxy-3-alkyl-isochinoline
GB810108A (en) 1955-09-13 1959-03-11 Cassella Farbwerke Mainkur Ag Phthalazine compounds basically substituted in the 1-position
US2892841A (en) 1956-04-02 1959-06-30 Grace W R & Co Process for aminating nitrogen-containing heterocyclic compounds
GB838994A (en) 1956-12-05 1960-06-22 Ici Ltd New anthradipyridazones and their use in polymeric materials
US2992220A (en) 1956-12-05 1961-07-11 Ici Ltd New anthra-1':9'(n):10'(n):5'-dipyridazones and anthra-1':9'(n):10'(n):4'-dipyridazones chemical compounds
US3247212A (en) 1963-03-19 1966-04-19 Dow Chemical Co Thio substituted 3 amino isoquinolines
US3291801A (en) 1963-05-23 1966-12-13 Grace W R & Co Novel octahydro-6(5)-phenanthridinones and preparation thereof
US3300499A (en) 1964-01-27 1967-01-24 Sterling Drug Inc 4-alkyl (or alkenyl)-1, 4-dihydro-1-oxobenzo [f] [1, 7] naphthyridine 2-carboxylic acid derivatives
CH461002A (de) 1965-08-11 1968-08-15 Ciba Geigy Verfahren zur Herstellung basischer wasserlöslicher Farbstoffe
US3403157A (en) 1965-09-01 1968-09-24 American Home Prod Benzo[6, 7]cyclohepta[1, 2, 3-d, e]isoquinoline derivatives
CH463778A (de) 1965-10-12 1968-10-15 Sandoz Ag Verfahren zur Erhöhung der Lichtbeständigkeit organischer nichttextiler Stoffe
DE1644596A1 (de) 1965-11-16 1971-05-06 Bayer Ag Farbstoffe und Verfahren zu deren Herstellung
US3557119A (en) 1967-04-11 1971-01-19 American Home Prod 2,3,7,8,9,9a-hexahydro-1h-benzo(d,e)(1,7) naphthyridine derivatives
FR7723M (de) 1967-06-22 1970-03-02
US3830816A (en) 1968-03-09 1974-08-20 Aspro Nicholas Ltd 1-cyclopropylmethyleneamino-3,4-dihydroisoquinoline and acid addition salts thereof
US3573304A (en) 1968-12-03 1971-03-30 Delalande Sa 1-dimethylamino - 3 - methyl-2(pyridyl or pyridazinyl) pentane and the corresponding non-toxic acid addition salts thereof
US3904671A (en) 1969-04-01 1975-09-09 Sterling Drug Inc Esters of 3-(hydroxy or hydroxymethyl)-4-hydroxyphenyl aminomethyl ketones
BE755131A (fr) 1969-08-22 1971-02-22 Merck Patent Gmbh 1,2,3, 11b-tetrahydropyrido/3,4,5:m,n/thioxanthenes, leurs selsd'addition acide et leurs procedes de preparation
FR2081572B1 (de) 1970-03-12 1973-04-06 Rhone Poulenc Sa
US3700673A (en) 1971-02-12 1972-10-24 Morton Norwich Products Inc 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
USRE31617E (en) 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3838134A (en) 1972-04-03 1974-09-24 G Gauthier Phenanthridinones as antiviral agents
GB1379111A (en) 1972-04-13 1975-01-02 Aspro Nicholas Ltd Preparation of fused-ring pyridine and pyrazine derivatives
CA1000701A (en) * 1972-07-19 1976-11-30 Ayerst, Mckenna And Harrison Process for preparing hexahydrobenzo (6,7) cyclohepta(1,2,3-de)isoquinolines
DE2355084A1 (de) 1972-11-06 1974-05-16 Guidotti & C Spa Labor Verbindungen mit magensaeuresekretionshemmender wirkung und verfahren zu deren herstellung
US4169897A (en) 1972-12-21 1979-10-02 Richardson-Merrell Inc. 2,7-bis-basic ethers of 9-phenanthrol and 9-loweralkoxy phenanthrol
US3899529A (en) 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
CH581113A5 (de) 1973-10-08 1976-10-29 Sandoz Ag
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3932643A (en) 1974-01-07 1976-01-13 Pfizer Inc. Phenanthridines and phenanthridinones as antiviral agents
US4031097A (en) 1974-09-09 1977-06-21 Eli Lilly And Company Descarboxylysergic acid
US3991064A (en) 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
BE839967R (fr) 1975-03-26 1976-09-24 Nouveaux derives de l'isoquinoleine, leur preparation et leur application comme medicaments
DE2557555C2 (de) 1975-12-20 1986-04-17 Hoechst Ag, 6230 Frankfurt Disazoverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Pigmente
GB1545767A (en) 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
JPS5337696A (en) 1976-08-26 1978-04-06 Omnium Chimique Sa Hexahydrocantinonee6 derivative
DE2650226A1 (de) 1976-11-02 1978-05-11 Henkel Kgaa 1,3,4-triaminoisochinolin, dessen herstellung sowie dieses enthaltende haarfaerbemittel
US4309543A (en) 1980-03-17 1982-01-05 Dynapol Process for preparing cyclic amides
DE3025385A1 (de) 1980-07-04 1982-01-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue tricyclische arylether, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
SE426653B (sv) * 1980-12-08 1983-02-07 Alfa Laval Ab Plattindunstare
US4472401A (en) 1981-11-27 1984-09-18 Roussel Uclaf Pyrimido-quinoxalines having antiallergic properties
US4594415A (en) 1982-03-29 1986-06-10 Robins Roland K Azole dinucleotide compositions and methods of use
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
CA1224148A (en) 1983-05-16 1987-07-14 John L. Haslam Drug delivery system utilizing thermosetting gels
JPS60187934U (ja) 1984-05-21 1985-12-12 富士電機株式会社 プログラマブルコントロ−ラ
US4639454A (en) 1985-01-17 1987-01-27 E. I. Du Pont De Nemours And Company Phenylquinazolinecarboxylic acids and derivatives as cancer chemotherapeutic agents
US4742171A (en) 1985-03-13 1988-05-03 Hoechst-Roussel Pharmaceuticals Inc. Method of synthesizing 1,4-dihydro-benzo[c]-1,5-naphthyridin-2(3H)-ones
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
DE3768922D1 (de) 1986-12-01 1991-05-02 Sumitomo Chemical Co Anthrapyridon-verbindungen, ihre herstellung und ihre verwendung.
US4740581A (en) 1987-02-24 1988-04-26 Eastman Kodak Company Condensation copolymers containing copolymerized isoquinoline derivative colorants and products therefrom
US5480631A (en) 1987-11-19 1996-01-02 Vanderbilt University Radioiodinated benzamines and method of their use as radioimaging
US4925968A (en) 1987-12-23 1990-05-15 American Home Products Corporation N-acyl-N-naphthoylglycines as aldose reductase inhibitors
US5274097A (en) 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
ATE117553T1 (de) 1988-08-19 1995-02-15 Warner Lambert Co Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren.
GB8830219D0 (en) 1988-12-23 1989-02-22 Zambeletti Spa L Novel compounds
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB8908229D0 (en) 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
JP2782009B2 (ja) 1989-10-28 1998-07-30 靖一 田沼 リグニン配糖体およびその用途
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5719151A (en) 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5077035A (en) 1990-05-14 1991-12-31 The University Of Michigan Radioiodinated benzovesamicol analogs for cholinergic nerve mapping
US5633282A (en) 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5635506A (en) 1990-06-26 1997-06-03 Research Corporation Technologies, Inc. 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents
ATE162526T1 (de) 1990-06-26 1998-02-15 Res Corp Technologies Inc 1,2-dihydro-3h-dibenzoisochinolin-1,3-dione als antitumormittel
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
WO1992015286A1 (en) 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
JP3185802B2 (ja) 1991-03-04 2001-07-11 ウェルファイド株式会社 ポリ（ａｄｐ−リボース）グリコヒドロラーゼ阻害剤
JP3067233B2 (ja) 1991-03-04 2000-07-17 ウェルファイド株式会社 アデノシン誘導体およびその用途
US5306889A (en) * 1991-07-05 1994-04-26 Sodick Co., Ltd. Wire cut electrical discharge machining apparatus
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5753674A (en) 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
DE59208852D1 (de) 1991-10-31 1997-10-09 Asta Medica Ag Neue Phthalazine, die in 1-Stellung eine Ether-Gruppierung enthalten und Verfahren zu deren Herstellung
US5264220A (en) 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
EP0661977A1 (de) * 1991-12-10 1995-07-12 Smithkline Beecham Corporation Behandlung von kolorektaler krebs
JP2989953B2 (ja) 1992-02-10 1999-12-13 富士ゼロックス株式会社 定着装置及び定着用エンドレスベルト
WO1993018748A1 (en) 1992-03-19 1993-09-30 Allergan, Inc. Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
US5235045A (en) 1992-03-19 1993-08-10 Microbiomed Corporation Non-azo naphthalimide dyes
US5414001A (en) 1992-05-29 1995-05-09 American Cyanamid Company Antineoplastic pyrrolo[4,3,2-de]quinolin-8(1H)-ones
JP3205402B2 (ja) 1992-09-09 2001-09-04 東芝アイティー・コントロールシステム株式会社 結晶方位決定方法及び装置
US5391554A (en) 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
AU5127893A (en) * 1992-09-11 1994-04-12 Research Corporation Technologies, Inc. 1,2 dihydro-3-h-dibenz(de,h) isoquinoline 1,3 dione and their use as anticancer agents
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5338851A (en) 1993-03-31 1994-08-16 Eli Lilly And Company Synthesis of cis-decahydroisoquinoline-3-carboxylic acids
US5373304A (en) * 1993-05-27 1994-12-13 Nolan; James F. Cellular phone antenna reflector
IT1265340B1 (it) 1993-07-14 1996-11-22 Istituto Biochimico Italiano Sostanze inibenti l'adp-ribosilazione proteica atte alla prevenzione delle complicanze del diabete mellito.
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5395835A (en) 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
CA2144783A1 (en) 1994-04-05 1995-10-06 Universiteit Van Pretoria Mdr resistance treatment
US5703089A (en) 1994-04-28 1997-12-30 Knoll Aktiengesellschaft Dihydrodibenzisoquinolinediones
WO1995029895A1 (en) 1994-04-28 1995-11-09 Knoll Aktiengesellschaft Dihydrodibenzo(de,h)isoquinolines derivatives and their use as anti-cancer agents
AU2402495A (en) 1994-05-05 1995-11-29 Merck Frosst Canada Inc. Topical polymeric drug delivery system
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
EP0723956B1 (de) * 1995-01-30 1999-10-13 Hoechst Aktiengesellschaft Basisch-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JPH11501934A (ja) 1995-03-14 1999-02-16 シャスカン，エドワード・ジー ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
CA2218679A1 (en) 1995-04-21 1996-10-24 Merck & Co., Inc. Apopain
US5618813A (en) 1995-05-26 1997-04-08 Abbott Laboratories Benzo[5.6]pyrano[2.3.4-ij]quinolizine and benzo[5.6]thiopyrano[2.3.4-ij]quinolizine derivatives as antibacterial and antineoplastic agents
US5767135A (en) 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
JP2000504730A (ja) 1996-02-15 2000-04-18 ケンブリッジ・ニューロサイエンス・インコーポレーテッド 製薬学的活性物質及び使用方法
CZ327698A3 (cs) 1996-04-13 1999-05-12 Astra Pharmaceuticals Ltd. Aminoisochinolinový a aminothienopyridinový derivát a jejich použití jako protizánětlivých přípravků
WO1998027975A1 (en) 1996-12-20 1998-07-02 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6235748B1 (en) 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
CN1213022C (zh) * 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
DE69831013T2 (de) * 1997-12-22 2006-04-20 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
TR200101498T2 (tr) 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6172245B1 (en) 1999-12-16 2001-01-09 Eastman Chemical Company Gas phase process for the epoxidation of non-allylic olefins
US6635506B2 (en) * 2001-11-07 2003-10-21 International Business Machines Corporation Method of fabricating micro-electromechanical switches on CMOS compatible substrates

Also Published As

Publication number Publication date
EP1212328B1 (de) 2006-08-02
US6716828B1 (en) 2004-04-06
MXPA02002213A (es) 2002-11-07
WO2001016137A1 (en) 2001-03-08
DE60029799T2 (de) 2007-08-16
JP2003508400A (ja) 2003-03-04
US7307080B2 (en) 2007-12-11
EP1212328A1 (de) 2002-06-12
CA2382317A1 (en) 2001-03-08
US20050074470A1 (en) 2005-04-07
DE60029799D1 (de) 2006-09-14
AU7087100A (en) 2001-03-26
US6291425B1 (en) 2001-09-18
CA2382317C (en) 2010-10-12

Similar Documents

Publication Publication Date Title
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
GB9903762D0 (en) Organic compounds
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
DE60039824D1 (de) Vorrichtung zur Behandlung von biologischen Geweben mittels Elektrizität oder Medikamenten
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE355288T1 (de) Verbindungen und therapeutische methoden
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties